Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial-Reference-Cited by-同舟云学术

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Published:2014-08 Issue:9 Volume:15 Page:943-953
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Taal Walter,Oosterkamp Hendrika M,Walenkamp Annemiek M E,Dubbink Hendrikus J,Beerepoot Laurens V,Hanse Monique C J,Buter Jan,Honkoop Aafke H,Boerman Dolf,de Vos Filip Y F,Dinjens Winand N M,Enting Roelien H,Taphoorn Martin J B,van den Berkmortel Franchette W P J,Jansen Rob L H,Brandsma Dieta,Bromberg Jacoline E C,van Heuvel Irene,Vernhout René M,van der Holt Bronno,van den Bent Martin J

Funder

Roche Netherlands and by grant number DDHK

Publisher

Elsevier BV

Subject

Oncology

Reference37 articles.

1. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med,2005

2. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial;Stupp;Lancet Oncol,2009

3. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma;Wick;J Clin Oncol,2010

4. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma;Batchelor;J Clin Oncol,2013

5. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma;Stark-Vance;Neuro-oncol,2005

Cited by 640 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy of stereotactic radiotherapy followed by bevacizumab and temozolomide in the treatment of recurrent glioblastoma: a case report;Frontiers in Pharmacology;2024-09-04

2. Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials;Cancers;2024-08-29

3. Targeting drug resistance in glioblastoma (Review);International Journal of Oncology;2024-07-09

4. The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis of randomized controlled trials;Frontiers in Medicine;2024-07-02

5. Stress granule-mediated sequestration of EGR1 mRNAs correlates with lomustine-induced cell death prevention;Journal of Cell Science;2024-06-15